WAYNE, Pa., May 15, 2026
Palvella Therapeutics announced new positive Phase 2 TOIVA trial data for QTORIN™ rapamycin in patients with cutaneous venous malformations (VMs) at the 83rd Annual Meeting of the Society for Investigative Dermatology. The findings showed statistically significant reductions in lesion bleeding and strong patient satisfaction, further strengthening the therapy’s potential to become the first FDA-approved treatment for cutaneous VMs, a rare vascular disorder affecting more than 75,000 people in the United States.
Significant Bleeding Reduction and Patient Satisfaction
The Phase 2 TOIVA study demonstrated that 100% of patients with bleeding at baseline experienced clinically meaningful improvement on the cVM-IGA Bleeding scale at Week 12, with a +2.5-point improvement (p=0.003). Importantly, all patients were rated as either “Much Improved” or “Very Much Improved”, highlighting the therapy’s strong therapeutic activity in controlling lesion bleeding — one of the most debilitating complications associated with cutaneous VMs.
In addition to clinician-assessed outcomes, patient-reported results were highly encouraging. Every patient with baseline bleeding reported being either “satisfied” or “very satisfied” with QTORIN™ rapamycin treatment at Week 12 based on the Treatment Satisfaction Questionnaire for Medication. Researchers noted that these findings reinforce the potential of topical QTORIN™ rapamycin to improve both clinical outcomes and overall quality of life in patients living with this chronic rare disease.
Trial Data Highlights Broad Quality-of-Life Benefits
Beyond efficacy measures, the study also included a patient-focused qualitative interview sub-study designed to evaluate the broader burden of cutaneous venous malformations. Patients described substantial physical and psychosocial challenges including pain, swelling, bleeding, lesion protrusions, bluish discoloration, emotional distress, and social limitations. Many participants reported difficulties with work, school activities, physical movement, and social interactions because of visible lesions and chronic symptoms.
Advertisement
Investigators emphasized that treatment priorities consistently centered around improving lesion appearance, reducing pain, and decreasing lesion size, demonstrating the importance of patient-reported outcomes in rare disease drug development. The findings align with the FDA’s Patient-Focused Drug Development framework and highlight the unmet medical need in this underserved patient population.
QTORIN Positioned as Potential First FDA-Approved Therapy
According to Palvella, QTORIN™ rapamycin is being developed as a once-daily topical therapy using the company’s proprietary QTORIN™ platform. The drug candidate has already shown positive efficacy across multiple pre-specified clinician-reported and patient-reported endpoints in the TOIVA study. The company believes the therapy has the potential to establish a new standard of care for cutaneous venous malformations, where there are currently no FDA-approved therapies available.
Experts presenting at the meeting stated that the reduction in lesion bleeding combined with meaningful quality-of-life improvements supports further advancement of the program toward later-stage clinical development and potential regulatory discussions.
Source: Palvella Therapeutics press release
